LXRX (Lexicon Corp) Earnings growth in current year

LXRX (Lexicon Corp) - company brandmark

Lexicon Pharmaceuticals (LXRX) relies on external contractors for drug manufacturing, ensuring quality through strict regulations. Management is striving for profitability while overcoming insurance coverage challenges. The annual EPS volatility confirms these processes, where the current status is -13.60. This underscores the company's status as a creator of unique molecules for metabolism regulation, opening new horizons in the treatment of diabetes.

LXRX: Lexicon Pharmaceuticals Earnings per share growth in current year 07/04/2022 - 11/15/2026

Financial and market metric breakdowns for Lexicon Pharmaceuticals Inc (LXRX)

- share price and expert price forecast:
Basic company analysis:LXRX - Lexicon Corp
Finished products of Lexicon Pharmaceuticals, Inc.

The diversification of the drug portfolio for the therapy of diabetes and cardiovascular pathologies directly determines the monetization efficiency of Lexicon Pharmaceuticals (LXRX) R&D assets. An analysis of the EPS trajectory compared to last year allows for an assessment of the net income growth rate per share, which serves as an indicator of capital density and reflects a shift in market consensus regarding the fundamental value of the business over the long term.

Main competitors

ASND: Net earnings per one share growth for the current year|MDGL (Madrigal Corp) - Earnings growth in current year|Earnings growth in current year Corcept Therapeutics|Earnings growth in current year RYTM|Earnings per share growth in current year AKRO (Akero Therapeutics, Inc.)|Earnings per share growth in current year metsera.com MTSR|MoonLake Corp (MLTX) - Earnings per share growth rate in current year|CRNX - Earnings per share growth in current year|NAMS: Earnings per share growth in current year|SLNO: Earnings growth in current year|FOLD - Expected net earnings per share growth this year|Earnings per share growth in current year 89bio Pharma|Agios Corp (AGIO) - Expected net earnings per share growth this year|Earnings per share growth in current year structuretx.com (GPCR)|Net earnings per share growth this year mimedx.com MDXG|Earnings per share growth in current year Rezolute RZLT|MBX Bio - Earnings per share growth in current year|ALT: Net earnings per share growth this year|AARD - Earnings growth in current year|SGMT: Earnings growth in current year|Earnings per share growth rate in current year BioAge Labs, Inc. (BIOA)|Earnings per share growth in current year Biomea Fusion Inc|Earnings per share growth this year QNCX (Quince Therapeutics)|Net earnings per share growth this year GUTS (Fractyl Health)|Net earnings per one share growth for the current year VTVT|Agape ATP Corporation - Net earnings per share growth this year|Earnings per share increase in current year PLUR|Synlogic Inc. - Earnings growth in current year|LPCN (Lipocine) - Earnings per share growth this year|MTNB (Matinas BioPharma Holdings Inc.) - Net earnings per share growth this year|SPRB (Spruce Biosciences, Inc.) - Earnings per share growth in current year|GLTO (galecto.com) - Earnings growth in current year|Net earnings per share growth this year carmellrx.com (CTCX)|Earnings per share growth in current year Lumos Pharma (LUMO)|ONVO (Organovo Holdings) - Earnings per share increase in current year|radiuspharm.com - Net earnings per share growth this year